Mouse in vivo neutralization of Escherichia coli Shiga toxin 2 with monoclonal antibodies

Toxins

Volumn 5, Issue 10, 2013, Pages 1845-1858

  Cheng, Luisa W ^a   Henderson, Thomas D ^a   Patfield, Stephanie ^a   Stanker, Larry L ^a   He, Xiaohua ^a  

^a WESTERN REGIONAL RESEARCH CENTER   (United States)

Author keywords

Monoclonal antibodies; Neutralization of shiga toxins; Shiga toxin producing E. coli; Toxicokinetics

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VEROTOXIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTION; FEMALE; FOOD CONTAMINATION; HALF LIFE TIME; HEMOLYTIC UREMIC SYNDROME; LD 50; LIMIT OF DETECTION; MOUSE; NONHUMAN; PATHOGEN CLEARANCE; POLLAKISURIA; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SURVIVAL; TOXICOKINETICS; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTIONS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; MICE; SHIGA TOXIN 2; SHIGA-TOXIGENIC ESCHERICHIA COLI;

EID: 84888150246     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins5101845     Document Type: Article

References (49)

1. Karrch, H.; Tarr, P.I.; Bielaszewska, M. Enterohaemorrhagic Escherichia coli in human medicine. Int. J. Med. Microbiol. 2005, 295, 405-418.
2. Manning, S.D.; Madera, R.T.; Schneider, W.; Dietrich, S.E.; Khalife, W.; Brown, W.; Whittam, T.S.; Somsel, P.; Rudrik, J.T. Surveillance for Shiga toxin-producing Escherichia coli, Michigan, 2001-2005. Emerg. Infect. Dis. 2007, 13, 318-321.
3. Trachtman, H.; Austin, C.; Lewinski, M.; Stahl, R.A. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat. Rev. Nephrol. 2012, 8, 658-669.
4. Scheutz, F.; Teel, L.D.; Beutin, L.; Pierard, D.; Buvens, G.; Karch, H.; Mellmann, A.; Caprioli, A.; Tozzoli, R.; Morabito, S.; Strockbine, N.A.; Melton-Celsa, A.R.; Sanchez, M.; Persson, S.; O'Brien, A.D. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J. Clin. Microbiol. 2012, 50, 2951-2963.
5. O'Brien, A.D.; Marques, L.R.; Kerry, C.F.; Newland, J.W.; Holmes, R.K. Shiga-like toxin converting phage of enterohemorrhagic Escherichia coli strain 933. Microb. Pathog. 1989, 6, 381-390.
6. Fraser, M.E.; Fujinaga, M.; Cherney, M.M.; Melton-Celsa, A.R.; Twiddy, E.M.; O'Brien, A.D.; James, M.N. Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J. Biol. Chem. 2004, 279, 27511-27517.
7. Reisbig, R.; Olsnes, S.; Eiklid, K. The cytotoxic activity of Shigella toxin. Evidence for catalytic inactivation of the 60 S ribosomal subunit. J. Biol. Chem. 1981, 256, 8739-8744.
8. Endo, Y.; Tsurugi, K.; Yutsudo, T.; Takeda, Y.; Ogasawara, T.; Igarashi, K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 1988, 171, 45-50.
9. Lingwood, C.A. Verotoxins and their glycolipid receptors. Adv. Lipid Res. 1993, 25, 189-211.
10. DeGrandis, S.; Law, H.; Brunton, J.; Gyles, C.; Lingwood, C.A. Globotetraosylceramide is recognized by the pig edema disease toxin. J. Biol. Chem. 1989, 264, 12520-12525.
11. Boerlin, P.; McEwen, S.A.; Boerlin-Petzold, F.; Wilson, J.B.; Johnson, R.P.; Gyles, C.L. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J. Clin. Microbiol. 1999, 37, 497-503.
12. Friedrich, A.W.; Bielaszewska, M.; Zhang, W.L.; Pulz, M.; Kuczius, T.; Ammon, A.; Karch, H. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J. Infect. Dis. 2002, 185, 74-84.
13. Wong, C.S.; Mooney, J.C.; Brandt, J.R.; Staples, A.O.; Jelacic, S.; Boster, D.R.; Watkins, S.L.; Tarr, P.I. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin. Infect. Dis. 2012, 55, 33-41.
14. Corogeanu, D.; Willmes, R.; Wolke, M.; Plum, G.; Utermohlen, O.; Kronke, M. Therapeutic concentrations of antibiotics inhibit Shiga toxin release from enterohemorrhagic E. coli O104:H4 from the 2011 German outbreak. BMC Microbiol. 2012, 12, 160.
15. Rosales, A.; Hofer, J.; Zimmerhackl, L.B.; Jungraithmayr, T.C.; Riedl, M.; Giner, T.; Strasak, A.; Orth-Holler, D.; Wurzner, R.; Karch, H. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin. Infect. Dis. 2012, 54, 1413-1421.
16. Wen, S.X.; Teel, L.D.; Judge, N.A.; O'Brien, A.D. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 2006, 24, 1142-1148.
17. Paton, A.W.; Morona, R.; Paton, J.C. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat. Med. 2000, 6, 265-270.
18. Bitzan, M. Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Int. Suppl. 2009, S62-S66.
19. Tzipori, S.; Sheoran, A.; Akiyoshi, D.; Donohue-Rolfe, A.; Trachtman, H. Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin. Microbiol. Rev. 2004, 17, 926-941, (table of contents).
20. Te Loo, D.M.; van Hinsbergh, V.W.; van den Heuvel, L.P.; Monnens, L.A. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2001, 12, 800-806.
21. Nowakowski, A.; Wang, C.; Powers, D.B.; Amersdorfer, P.; Smith, T.J.; Montgomery, V.A.; Sheridan, R.; Blake, R.; Smith, L.A.; Marks, J.D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 2002, 99, 11346-11350.
22. Bitzan, M.; Klemt, M.; Steffens, R.; Muller-Wiefel, D.E. Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls. Infection 1993, 21, 140-145.
23. Mohawk, K.L.; Melton-Celsa, A.R.; Robinson, C.M.; O'Brien, A.D. Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7. Vaccine 2010, 28, 4777-4785.
24. Yamagami, S.; Motoki, M.; Kimura, T.; Izumi, H.; Takeda, T.; Katsuura, Y.; Matsumoto, Y. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J. Infect. Dis. 2001, 184, 738-742.
25. Jeong, K.I.; Tzipori, S.; Sheoran, A.S. Shiga toxin 2-specific but not shiga toxin 1-specific human monoclonal antibody protects piglets challenged with enterohemorrhagic Escherichia coli producing shiga toxin 1 and shiga toxin 2. J. Infect. Dis. 2010, 201, 1081-1083.
26. Sauter, K.A.; Melton-Celsa, A.R.; Larkin, K.; Troxell, M.L.; O'Brien, A.D.; Magun, B.E. Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody. Infect. Immun. 2008, 76, 4469-4478.
27. Mukherjee, J.; Chios, K.; Fishwild, D.; Hudson, D.; O'Donnell, S.; Rich, S.M.; Donohue-Rolfe, A.; Tzipori, S. Production and characterization of protective human antibodies against Shiga toxin 1. Infect. Immun. 2002, 70, 5896-5899.
28. Padhye, V.V.; Zhao, T.; Doyle, M.P. Production and characterisation of monoclonal antibodies to Verotoxins 1 and 2 from Escherichia coli of serotype O157:H7. J. Med. Microbiol. 1989, 30, 219-226.
29. Parma, Y.R.; Chacana, P.A.; Roge, A.; Kahl, A.; Cangelosi, A.; Geoghegan, P.; Lucchesi, P.M.; Fernandez-Miyakawa, M.E. Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: isolation, purification and neutralization efficacy. Toxicon 2011, 58, 380-388.
30. Rutjes, N.W.; Binnington, B.A.; Smith, C.R.; Maloney, M.D.; Lingwood, C.A. Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int. 2002, 62, 832-845.
31. Kimura, T.; Tani, S.; Motoki, M.; Matsumoto, Y. Role of Shiga toxin 2 (Stx2)-binding protein, human serum amyloid P component (HuSAP), in Shiga toxin-producing Escherichia coli infections: assumption from in vitro and in vivo study using HuSAP and anti-Stx2 humanized monoclonal antibody TMA-15. Biochem. Biophys. Res. Commun. 2003, 305, 1057-1060.
32. Jeong, K.I.; Chapman-Bonofiglio, S.; Singh, P.; Lee, J.; Tzipori, S.; Sheoran, A.S. In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2. BMC Immunol. 2010, 11, 16.
33. March, S.B.; Ratnam, S. Sorbitol-MacConkey medium for detection of Escherichia coli O157:H7 associated with hemorrhagic colitis. J. Clin. Microbiol. 1986, 23, 869-872.
34. He, X.; McMahon, S.; Skinner, C.; Merrill, P.; Scotcher, M.C.; Stanker, L.H. Development and characterization of monoclonal antibodies against Shiga toxin 2 and their application for toxin detection in milk. J. Immunol. Methods 2013, 389, 18-28.
35. Cheng, L.W.; Stanker, L.H.; Henderson, T.D., 2nd; Lou, J.; Marks, J.D. Antibody protection against botulinum neurotoxin intoxication in mice. Infect. Immun. 2009, 77, 4305-4313.
36. Liu, Y.N.; Wang, S.H.; Li, T.; Wang, Q.; Tu, W.; Cai, K.; Hou, X.J.; Tian, R.M.; Gao, X.; Liu, H.; Xiao, L.; Shi, J.; Cheng, Y.G.; Li, J.C.; Wang, H. Shiga toxin type 2 (Stx2), a potential agent of bioterrorism, has a short distribution and a long elimination half-life, and induces kidney and thymus lesions in rats. Arch. Toxicol. 2011, 85, 1133-1140.
37. Sheoran, A.; Jeong, K.I.; Mukherjee, J.; Wiffin, A.; Singh, P.; Tzipori, S. Biodistribution and elimination kinetics of systemic Stx2 by the Stx2A and Stx2B subunit-specific human monoclonal antibodies in mice. BMC Immunol. 2012, 13, 27.
38. Mukherjee, J.; Chios, K.; Fishwild, D.; Hudson, D.; O'Donnell, S.; Rich, S.M.; Donohue-Rolfe, A.; Tzipori, S. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 2002, 70, 612-619.
39. Johansson, A.G.; Lovdal, T.; Magnusson, K.E.; Berg, T.; Skogh, T. Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Hepatology 1996, 24, 169-175.
40. Sepulveda, J.; Mukherjee, J.; Tzipori, S.; Simpson, L.L.; Shoemaker, C.B. Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect. Immun. 2010, 78, 756-763.
41. Chow, S.K.; Smith, C.; MacCarthy, T.; Pohl, M.A.; Bergman, A.; Casadevall, A. Diseaseenhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodies. Cell Host Microbe 2013, 13, 417-428.
42. Fuller, C.A.; Pellino, C.A.; Flagler, M.J.; Strasser, J.E.; Weiss, A.A. Shiga toxin subtypes display dramatic differences in potency. Infect. Immun. 2011, 79, 1329-1337.
43. Donohue-Rolfe, A.; Kondova, I.; Mukherjee, J.; Chios, K.; Hutto, D.; Tzipori, S. Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2. Infect. Immun. 1999, 67, 3645-3648.
44. Vieira, P.; Rajewsky, K. The half-lives of serum immunoglobulins in adult mice. Eur. J. Immunol. 1988, 18, 313-316.
45. Ariceta, G.; Besbas, N.; Johnson, S.; Karpman, D.; Landau, D.; Licht, C.; Loirat, C.; Pecoraro, C.; Taylor, C.M.; Van de Kar, N.; Vandewalle, J.; Zimmerhackl, L.B. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr. Nephrol. 2009, 24, 687-696.
46. Tarr, P.I. Escherichia coli O157:H7: clinical, diagnostic, and epidemiological aspects of human infection. Clin. Infect. Dis. 1995, 20, 1-8, quiz 9-10.
47. Safdar, N.; Said, A.; Gangnon, R.E.; Maki, D.G. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 2002, 288, 996-1001.
48. Reed, L.J.; Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 1938, 27, 493.
49. Weil, C.S. Tables for the convenient calculation of median-effective dose (LD50 or ED50) and instructions in their use. Biometrices 1952, 8, 249-263.